Figure 6.

Health Canada dosing regimens for the treatment of venous thromboembolic events and prevention of deep vein thrombosis and pulmonary embolism. Depicted are the Health Canada approved dosing regimens for (A) dabigatran, (B) apixaban, (C) edoxaban and (D) rivaroxaban.^{6–9 *}Dabigatran 110 mg twice a day (BID) should be considered for patients ⩾ 80 years, or those at higher risk of bleeding (⩾75 years with ⩾1 risk factor for bleeding). ^$Edoxaban 30 mg once a day (OD) is recommended for moderate renal impairment (creatinine clearance 30–50 ml/min), weight ⩽ 60 kg, or concomitant use of P-glycoprotein inhibitors (except amiodarone and verapamil).